Literature Review and Case Summary: Exploring Deafness as an Adverse Reaction to Bortezomib

Key Points

• Deafness is a significant adverse reaction observed in patients undergoing treatment with bortezomib, impacting quality of life.
• Key evidence includes multiple case reports linking bortezomib with hearing loss in a subset of patients.
• Literature review addresses various case summaries and peer-reviewed articles to outline the phenomenon of deafness.
• The findings highlight the need for heightened clinical vigilance when prescribing bortezomib due to its potential ototoxic effects.